secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001493152-24-035144
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies
--------------------------------------------------------------------------------

- U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.
- Patent covers combining LIXTE's LB-100 PP2A inhibitor with various innovative cancer immunotherapies.
- CEO Bastiaan van der Baan says patent bolsters IP portfolio and commitment to cancer innovation.
- LB-100 is being tested in clinical trials with Roche's atezolizumab (colon cancer) and GSK's dostarlimab (ovarian cancer).
- Follows exclusive patent license agreement earlier this year with NINDS and NCI of the NIH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224035144/0001493152-24-035144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224035144/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer